An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study. Using data from 28 major U.S. cancer centers, the researchers examined the association between glucarpidase treatment—which rapidly clears MTX from the blood—and outcomes of patients with MTX-induced acute kidney injury (AKI). They found that patients who received glucarpidase had significantly higher chances of kidney recovery compared to those who did not get this treatment. "Glucarpidase is unique because it's one of the very few potential antidotes available to counteract the high rates of toxicity...